Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT05642364 for End Stage Kidney Disease, Depressive Symptoms is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Virtual Reality in Hemodialysis to Improve Psychological Well-being 61 Biomarker-Driven Randomized Virtual
Clinical Trial NCT05642364 is an interventional study for End Stage Kidney Disease, Depressive Symptoms that is active, not recruiting. It started on 22 June 2023 with plans to enroll 61 participants. Led by University of Illinois at Urbana-Champaign, it is expected to complete by 31 March 2026. The latest data from ClinicalTrials.gov was last updated on 18 February 2026.
Brief Summary
The long-term goal is to create behavioral health technologies to advance the science that leverages state-of-the-art technology to delivery psychotherapeutic treatment to individuals on hemodialysis (HD) to improve their emotional well-being, quality of life, and overall health. The objective in this small R01 study is to design a virtual reality (VR) platform, that fully immerses users into a fictitious lifelike en...Show More
Detailed Description
Hemodialysis (HD) is a taxing procedure with extensive illness burden and arduous self-care demands. As such, more than 30% of individuals on HD experience elevated symptoms of depression-and, research shows that comorbid depression is associated with adverse kidney disease outcomes, greater risk of hospitalization, and decreased survival rates. Current interventions to treat depressive symptoms in individuals on HD ...Show More
Official Title
Positive Psychological Intervention Delivered Using Virtual Reality in Hemodialysis Patients With Comorbid Depression: Randomized Controlled Trial Assessing Feasibility and Efficacy Testing
Conditions
End Stage Kidney DiseaseDepressive SymptomsPublications
Scientific articles and research papers published about this clinical trial:Other Study IDs
NCT ID Number
Start Date (Actual)
2023-06-22
Last Update Posted
2026-02-18
Completion Date (Estimated)
2026-03-31
Enrollment (Estimated)
61
Study Type
Interventional
PHASE
N/A
Status
Active, not recruiting
Keywords
Positive psychological intervention
Positive emotion
Virtual reality
Psychotherapy
Technology
Head-mounted display
Positive emotion
Virtual reality
Psychotherapy
Technology
Head-mounted display
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
Double
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalVirtual Reality Treatment VR-delivered JovialityTM Sessions: Treatment Group. Participants will interact with a newly-developed VR environment over a 5-week period, during regularly scheduled maintenance HD treatment. Each week, enrollees will be introduced to a new skill, all taught in distinctive VR environments-with immersive sessions lasting no more than 30 minutes. The investigators' 5-week positive psychological intervention covers the ...Show More | Joviality(TM) 5-week positive psychological intervention delivered using 3D virtual reality software that is immersive and uses a head-mounted display |
Active ComparatorInert Virtual Reality Participants randomized to the control arm will receive a rigorous placebo following clinical trial guidelines of VR-CORE, which consists of 2-dimensional (2D) non-immersive visual content displayed on the head-mounted display. Footage of wildlife and nature-based settings are visually displayed as part of the 'Sham' VR with inert music that does not promote high levels of relaxation or distraction. The 'Sham' VR exp...Show More | Inert Virtual Reality Participants randomized to the control arm will receive a rigorous placebo following clinical trial guidelines of VR-CORE, which consists of 2-dimensional (2D) non-immersive visual content displayed on the head-mounted display. Footage of wildlife and nature-based settings are visually displayed as part of the Sham VR with inert music that does not promote high levels of relaxation or distraction. |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Feasibility: Recruitment | Proportion of potential enrollees who were approached for recruitment. | Through study completion, an average 6 months. |
Feasibility: Retention rates | Defined as completing all post-intervention assessments, categorized as a binary outcome Target: ≥75% | Post-intervention at 6-months |
Feasibility: Non-Compliance/Adherence | Measured by the proportion of the intervention completed (e.g., number of virtual reality environments viewed out of the total possible available across skill lessons in the intervention). Target: ≥75% | Immediately post-intervention at 5-weeks |
Feasibility: Refusal rates | Proportion of potential enrollees who were approached for recruitment but decided not to enroll. | Before enrollment |
Acceptability as assessed by whether a participant would recommend the JovialityTM software | Acceptability as measured by whether a participant would recommend JovialityTM to other HD patients (0 definitely not, to 10 definitely yes). Target: ≥8.0 | Immediately post-intervention at 5-weeks |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Depressive symptoms | Depressive symptomatology will be assessed using the Beck Depression Inventory-II. Scores range from 1 to 40 where a higher score indicates worse symptoms of depression. | Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention) |
Kidney Disease and Quality of Life | Kidney Disease and Quality of Life (KDQOL-SF™). The scoring procedure first transforms the raw precoded numeric values of items to a 0-100 possible range, with higher transformed scores reflecting better quality of life. | Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention) |
Number of missed hemodialysis treatment sessions | Research staff will extract information from patient medical records to record the number of missed hemodialysis treatment sessions | Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention) |
Emergency department visits and/or hospitalizations | Research staff will extract information from patient medical records to record the number of emergency department visits and days of hospitalizations. | Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention) |
Patient-Reported Outcomes Measurement Information System (PROMIS) computer adaptive test for depressive symptoms | The Patient-Reported Outcomes Measurement Information System (PROMIS) computer adaptive test for depressive symptoms (range values: 28- 140) will serve as an additional measure to triangulate findings of the Beck Depression Inventory-II.
A higher PROMIS T-score represents more of the concept being measured. | Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention) |
Patient-Reported Outcomes Measurement Information System (PROMIS) for anxiety | The PROMIS adaptive measures for anxiety (range values: 29-145) will be used. A higher PROMIS T-score represents more of the concept being measured. | Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention) |
Patient-Reported Outcomes Measurement Information System (PROMIS) for perceived stress | The PROMIS adaptive measures for perceived stress (range values: 29-145) will be used.
A higher PROMIS T-score represents more of the concept being measured. | Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention) |
Patient-Reported Outcomes Measurement Information System (PROMIS) for life satisfaction | The PROMIS adaptive measures for life satisfaction (range values: 10-60) will be used. A higher PROMIS T-score represents more of the concept being measured. | Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention) |
Patient-Reported Outcomes Measurement Information System (PROMIS) for positive affect | The PROMIS adaptive measures for positive affect (range values: 34-170) will be used.
A higher PROMIS T-score represents more of the concept being measured. | Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention) |
Patient-Reported Outcomes Measurement Information System (PROMIS) for life meaning and purpose | The PROMIS adaptive measures for life meaning and purpose (range values 4-60) will be used. A higher PROMIS T-score represents more of the concept being measured. | Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention) |
Patient-Reported Outcomes Measurement Information System (PROMIS) for self-efficacy for managing emotions in the context of a chronic condition | The PROMIS adaptive measures for self-efficacy for managing emotions in the context of a chronic condition (range values: 25-125) will be used. A higher PROMIS T-score represents more of the concept being measured. | Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention) |
Psychological well-being measured with the 7-item State Optimism Measure | Additional measures of psychological well-being will include the optimism using the 7-item State Optimism Measure. Scoring is mean score of items 1-7 with a higher score indicating greater state optimism. | Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention) |
Psychological well-being measured with the Emotional Vitality Measure | Additional measures of psychological well-being will also include emotional vitality (range values 0-110), as measured using select items of the General Well-being Schedule. There are three proposed cut-points: total scores of 0-60 reflect "severe distress", 61-72 "moderate distress" and 73-110 "positive well-being" | Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention) |
Psychological well-being measured with the Flourishing Index | The "Flourish" measure is obtained by summing the scores from each of the first five domains. The "Secure Flourish" measure is obtained by summing the scores from all six domains including the financial and material stability domain. Each of the questions is assessed on a scale of 0-10.
The secure flourishing index score is obtained by summing the scores from the twelve questions in all six domains and results in a score from 0 - 120. Often, for purposes of interpretation, the flourishing and secure flourishing scores are reported as averages of the questions (rather than sums) so that all scores are on a scale of 0-10. | Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention) |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
21 Years
Eligible Sexes
All
- 1) HD patient with at least three months since treatment initiation
- 2) Beck Depression Inventory-II (BDI-II) score ≥11
- 3) age 21 or older
- 4) visual and audio acuity to immerse in our VR world
- 5) fluent in English or Spanish
- 1) unavailable for study period
- 2) prevalent cognitive impairment denoting dementia
- 3) physical limitation restricting use of a head-mounted display
- 4) history of epilepsy, seizures, or vertigo.
Study Responsible Party
Rosalba Hernandez, Principal Investigator, Associate Professor, University of Illinois at Urbana-Champaign
No contact data.
3 Study Locations in 1 Countries
Illinois
DaVita Little Village Dialysis PD, Chicago, Illinois, 60608, United States
UI Health - Dialysis Unit, EEI Suite 2028, Chicago, Illinois, 60612, United States
DaVita Garfield Kidney Center, Chicago, Illinois, 60624, United States